BRITISH COLUMBIA, Canada, July 18, 2005 (PRIMEZONE) -- BioCurex, Inc. (Pink Sheets:BOCX) announced today that Dr. Gerald Wittenberg, chairman and co-founder of BioCurex, Inc., has conducted an exclusive webcast with The Green Baron so that BOCX shareholders and the investment community can learn more about the current status of BioCurex, Inc. The interview includes discussion of the licensing agreement which BioCurex completed with a global healthcare company as well as a commentary on the future prospects of the Company. The webcast was be conducted by Evergreen Marketing, Inc. and their subsidiary TheGreenBaron.com and is now available for listening on The Green Baron Investors Society's website at www.TheGreenBaron.com.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging, and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types, but is absent in most normal or benign cells. To read more about the Company, please visit the news section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.